Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 5631 | Other Identifier | Signe and Ane Gyllenbergs foundation | |
| 1111 | Other Grant/Funding Number | Prima Psychiatry internal research fund |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Emotional Awareness and Expression Therapy (EAET) has emerged as a promising approach for addressing persistent physical symptoms (PPS). Investigating EAET within the context of routine psychiatric care is crucial for several reasons:
Many patients with PPS experience significant distress and functional impairment, yet traditional medical treatments often fail to provide adequate relief. Integrating EAET into routine care could offer a valuable therapeutic option for this population.
Preliminary studies suggest that EAET can lead to significant reductions in pain and other somatic symptoms. Investigating its effectiveness in routine care settings could enhance treatment outcomes for patients who have not responded to conventional therapies.
There is often a disconnect between mental health and physical health treatment in routine care. Investigating EAET can help bridge this gap, fostering collaboration between mental health professionals and primary care providers to address the complexities of patients' health issues.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Emotional Awareness and Expression Therapy | Other | Please see description for intervention |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Emotional Awareness and Expression Therapy (EAET) | Behavioral | Emotional Awareness and Expression Therapy (EAET) is a manualized, short-term psychodynamic therapy that, in this instance, is delivered in a group format. The core of Emotional Awareness and Expression Therapy (EAET) involves helping individuals identify, understand, and express their emotions in a therapeutic setting. The therapy emphasizes the connection between unprocessed emotions and physical symptoms, encouraging participants to explore the emotional underpinnings of their distress. Through guided discussions, psychoeducation, and expressive exercises, participants learn to recognize patterns of emotional avoidance, develop self-compassion, and improve interpersonal communication. This process aims to reduce somatic symptoms and enhance overall emotional well-being by fostering a greater awareness of emotional experiences. |
| Measure | Description | Time Frame |
|---|---|---|
| Patient Health Questionnaire-15 (PHQ-15) | Somatic symptom severity during the "last week " are assessed with the Patient Health Questionnaire-15 (PHQ-15). Items are rated 0 ("not bothered at all"), 1 ("bothered a little"), or 2 ("bothered a lot"); total scores range from 0 to 30. | Pre-post treatment (at treatment termination) |
| Visual Analoge Scales | A second primary outcome is the two Visual Analoge Scales suggested by the EURONET-SOMA network (Rief et al., 2017). Somatic symptom intensity is measured from 1 ("No symptom") to 10 ("Symptom as bad as you can imagine") and somatic symptom interference from 1 ("No interference") to 10 ("Maximum interference"). | Pre-post treatment (at treatment termination) |
| Measure | Description | Time Frame |
|---|---|---|
| Sheehan Disability Scale | SDS consist on three visual analogue scales ranging from 0-10 for symptom interference in daily life. Higher scores indicate worse symptom/functioning, with a maximum score of 30. | 1. Pre-post treatment (at treatment termination). 2. Pre-Follow up (12 weeks after intervention). |
| Post traumatic symptom Check List-5 (PCL-5), |
| Measure | Description | Time Frame |
|---|---|---|
| Credibility and Expectancy Questionaire (CEQ) | The questionnaire consists of several items that participants respond to on a Likert scale (e.g., from 1 to 7), where they rate their level of agreement or belief regarding various statements related to the treatment's credibility and their expected outcomes. | Three weeks into treatment |
Inclusion Criteria:
Exclusion Criteria:
Please note that it is the chief physician of each respective research sponsor who, based on collected anamnesis and self-assessment information, makes the final decision regarding whether a participant should be included or excluded from the research project.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Daniel L A Maroti, PhD | Contact | 46738028474 | daniel.maroti@su.se |
| Name | Affiliation | Role |
|---|---|---|
| Daniel Maroti, PhD | Department of Psychology, Faculty of Social Sciences, Stockholm University | Principal Investigator |
Not provided
The participants has not agreed to this
Not provided
Not provided
Not provided
Not provided
Not provided
Pilot study
Not provided
Not provided
Not provided
Not provided
|
PCL-5 consists of 20 questions with ratings 0-4 on impact of post traumatic symptoms. Higher scores indicate worse symptom/functioning with a maximum score of 80. |
| 1. Pre-post treatment (at treatment termination). 2. Pre-Follow up (12 weeks after intervention). |
| Patient Health Questionaire-9 (PHQ-9) | PHQ-9 consists of nine questions withs ratings 0-3 (0= "not at all", 3= "almost every day") on impact of depressive symptoms. Higher scores indicate worse symptom/functioning with a maximum score of 27. | 1. Pre-post treatment (at treatment termination). 2. Pre-Follow up (12 weeks after intervention). |
| Generalized Anxiety Disorder 7-item scale (GAD-7) | GAD-7 consists of seven questions with ratings 0-3 (0= "not at all", 3= "almost every day") on impact of anxiety symptoms. Higher scores indicate worse symptom/functioning functioning with a maximum score of 21. | 1. Pre-post treatment (at treatment termination). 2. Pre-Follow up (12 weeks after intervention). |
| Visual Analoge Scales | Visual Analoge Scales suggested by the EURONET-SOMA network (Rief et al., 2017). Somatic symptom intensity is measured from 1 ("No symptom") to 10 ("Symptom as bad as you can imagine") and somatic symptom interference from 1 ("No interference") to 10 ("Maximum interference"). | Pre-FU (12 weeks after intervention) |
| Patient Health Questionaire-15 (PHQ-15) | Somatic symptom severity during the "last week" was assessed with the PHQ-15. Items were rated 0 ("Not bothered at all"), 1 ("Bothered a little"), or 2 ("Bothered a lot"); total scores range from 0 to 30 for women and 0-27 for men. | Pre-FU (12 weeks after intervention) |
| Negative Effects Questionnaire (NEQ) |
The questionnaire includes a series of statements or questions that participants respond to using a Likert scale, where they indicate how often they have experienced these negative effects. |
| At FU (12 weeks after intervention). |
| 8 visual analgue scales | 2 question on 1-10 on symptom intensity and inferference 2 questions on 1-10 on the capacity of self-compassion 2 questions on 1-10 on the capacity of emotional processing 2 question on 1-10 on symptom attribution | Mediational measure: Every week during the 12 week long treatment (i.e. 11 measurement points.) |